PI

Dr. XIONG Bing is a professor of Shanghai Institute of Materia Medica (SIMM), CAS. He earned the Ph.D degree in medicinal chemistry from Chinese Academy of Sciences (2001-2003), and did the postdoctoral training in structure biology at McGill University, Canada (2003-2005). Currently, his research focuses on the structure/fragment-based drug discovery in epigenetics. His group has built an integrated platform by assembling technologies in computational chemistry, structural biology and medicinal chemistry, providing innovation in lead identification and optimization. He has published more than 120 research articles in peer-review journals including Journal of Medicinal Chemistry, ChemMedChem, PLOS One, Bioorg. Med. Chem. Lett., Bioorg. Med. Chem, EJMC, Bioinformatics, BMC Bioinformatics, journal of computer information and modeling, JCC. Dr. XIONG has received a number of awards including CPA-Servier Young Investigator Awards in Medicinal Chemistry. His group has transformed several achievements to drug companies, and two drug candidates now entered into clinical trials and Gumarontinib (谷美替尼，SCC244）has been approved for treatment of non-small cell lung cancer with MET Exon 14 skipping mutation in China and Japan.